Electrolysed-reduced water dialysate improves T-cell damage in end-stage renal disease patients with chronic haemodialysis.
Kuo-Chin Huang, Shih-Ping Hsu, Chih-Ching Yang, Pu Ou-Yang, Kun-Tai Lee, Shinkatsu Morisawa, Kazumichi Otsubo, Chiang-Ting Chien · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2010
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 42 patients with ERW for 1 year, the intracellular IL-2 and IFN-gamma levels in the Th1/Tc1 cells significantly (P < 0.05) increased and the intracellular IL-4, IL-6 and IL-10 levels in the Th2/Tc2 cells decreased. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 42 patients with ERW for 1 year. The intracellular IL-2 and IFN-gamma levels in the Th1/Tc1 cells significantly (P < 0.05) increased and the intracellular IL-4, IL-6 and IL-10 levels in the Th2/Tc2 cells decreased.
What the Researchers Studied
The researchers studied 42 patients with ERW for 1 year. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
The researchers evaluated apoptosis formation by annexin V, CD25-related surface markers, and cytokine ratio of Th1/Th2 in CD4(+) T lymphocytes and Tc1/Tc2 in CD8(+) T lymphocytes of 42 ESRD patients haemodialysed with ERW for 1 year. The intracellular IL-2 and IFN-gamma levels in the Th1/Tc1 cells significantly (P < 0.05) increased and the intracellular IL-4, IL-6 and IL-10 levels in the Th2/Tc2 cells decreased.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 42 patients with ERW for 1 year. The study used a human clinical study.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.